BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012;118:3984-3992. [PMID: 22180222 DOI: 10.1002/cncr.26726] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Li Z. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. Front Med 2017;11:509-21. [DOI: 10.1007/s11684-017-0546-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
2 Chan SL. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;36:74-5. [DOI: 10.1111/j.1365-2036.2012.05125.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH. High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Transl Oncol 2013;6:311-8. [PMID: 23730411 DOI: 10.1593/tlo.12418] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
4 Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:1529-1535. [PMID: 25968302 DOI: 10.1111/jgh.13005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: An Asian perspective: Editorial. Asia-Pacific Journal of Clinical Oncology 2012;8:111-4. [DOI: 10.1111/j.1743-7563.2012.01551.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J, Bazhin AV. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer 2015;112:1027-36. [PMID: 25742476 DOI: 10.1038/bjc.2015.72] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
7 Cunha LL, Morari EC, Nonogaki S, Marcello MA, Soares FA, Vassallo J, Ward LS. Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. Cancer Immunol Immunother 2017;66:141-8. [DOI: 10.1007/s00262-016-1924-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
8 Wong K, Xu Z, Chen J, Lee NP, Luk JM. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2013;7:319-29. [DOI: 10.1517/17530059.2013.795146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
9 Cho HJ, Baek GO, Seo CW, Ahn HR, Sung S, Son JA, Kim SS, Cho SW, Jang JW, Nam SW, Cheong JY, Eun JW. Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. Cancer Med 2020;9:5459-72. [PMID: 32537885 DOI: 10.1002/cam4.3230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
10 Niu W, Pang Q, Lin T, Wang Z, Zhang J, Tai M, Zhang L, Zhang L, Gu M, Liu C, Qu K. A Causal Role of Genetically Elevated Circulating Interleukin-10 in the Development of Digestive Cancers: Evidence from Mendelian Randomization Analysis Based on 29,307 Subjects. Medicine (Baltimore) 2016;95:e2799. [PMID: 26886630 DOI: 10.1097/MD.0000000000002799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Chen VL, Le AK, Podlaha O, Estevez J, Li B, Vutien P, Chang ET, Rosenberg-Hasson Y, Pflanz S, Jiang Z, Ge D, Gaggar A, Nguyen MH. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. Sci Rep. 2017;7:11169. [PMID: 28894136 DOI: 10.1038/s41598-017-10498-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
12 Arantes DA, Costa NL, Mendonça EF, Silva TA, Batista AC. Overexpression of immunosuppressive cytokines is associated with poorer clinical stage of oral squamous cell carcinoma. Arch Oral Biol 2016;61:28-35. [PMID: 26513679 DOI: 10.1016/j.archoralbio.2015.10.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
13 Zhao S, Wu D, Wu P, Wang Z, Huang J. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. PLoS One. 2015;10:e0139598. [PMID: 26440936 DOI: 10.1371/journal.pone.0139598] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
14 Wang Y, Liu XH, Li YH, Li O. The paradox of IL-10-mediated modulation in cervical cancer. Biomed Rep 2013;1:347-51. [PMID: 24648946 DOI: 10.3892/br.2013.69] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
15 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-7300 [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
16 Wu J, Ma XL, Tian L, Zhang CY, Wang BL, Hu YY, Gao XH, Zhou Y, Shen MN, Peng YF, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. J Cancer 2017;8:1338-46. [PMID: 28638447 DOI: 10.7150/jca.18030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
17 Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol 2014; 20(12): 3135-3145 [PMID: 24696599 DOI: 10.3748/wjg.v20.i12.3135] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
18 Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, Mok K, Liu C, Chong CC, Chan AT, Mok T, Yeo W. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int 2017;37:280-9. [DOI: 10.1111/liv.13218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
19 Cao W, Mo K, Wei S, Lan X, Zhang W, Jiang W. Effects of rosmarinic acid on immunoregulatory activity and hepatocellular carcinoma cell apoptosis in H22 tumor-bearing mice. Korean J Physiol Pharmacol 2019;23:501-8. [PMID: 31680772 DOI: 10.4196/kjpp.2019.23.6.501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chan SL, Chan AW, Yeo W. Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets 2015;19:973-83. [DOI: 10.1517/14728222.2015.1031109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Qian Q, Wu C, Chen J, Wang W. Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. Biomed Res Int. 2020;2020:8910183. [PMID: 32724815 DOI: 10.1155/2020/8910183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Li ZQ, He YX, Geng JH, Jiang QH, Liu J, Zhang FY. Effect of treatment with PEG-IFNα on serum levels of IFN-γ, IL-17 and IL-10 in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2016; 24(1): 116-120 [DOI: 10.11569/wcjd.v24.i1.116] [Reference Citation Analysis]
23 Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013;10:380-386. [PMID: 23350952 DOI: 10.3109/1547691x.2012.758198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
24 Zhen H, Qian X, Fu X, Chen Z, Zhang A, Shi L. Regulation of Shaoyao Ruangan Mixture on Intestinal Flora in Mice With Primary Liver Cancer. Integr Cancer Ther 2019;18:1534735419843178. [PMID: 31006277 DOI: 10.1177/1534735419843178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013;9:2-5. [PMID: 23418846 DOI: 10.1111/ajco.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
26 Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062-1070. [PMID: 30256409 DOI: 10.1002/jcp.27324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Chen C, Sung W, Su T, Chen M, Wu P, Yeh K, Ko J, Lee H. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clinica Chimica Acta 2013;415:25-30. [DOI: 10.1016/j.cca.2012.09.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
28 Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, Jiang Y, Yang Z. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer 2021;21:246. [PMID: 33685417 DOI: 10.1186/s12885-021-07916-3] [Reference Citation Analysis]
29 Hatab HM, Abdel Hamid FF, Soliman AF, Al-Shafie TA, Ismail YM, El-Houseini ME. A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study. J Gastrointest Oncol 2019;10:766-76. [PMID: 31392057 DOI: 10.21037/jgo.2019.03.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
30 Timperi E, Barnaba V. Viral Hepatitides, Inflammation and Tumour Microenvironment. Adv Exp Med Biol 2020;1263:25-43. [PMID: 32588321 DOI: 10.1007/978-3-030-44518-8_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118:248-257. [PMID: 29123264 DOI: 10.1038/bjc.2017.386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
32 Wang J, Luo J, Yin X, Huang W, Cao H, Wang G, Wang J, Zhou J. Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Biomed Res Int 2019;2019:4696843. [PMID: 31341898 DOI: 10.1155/2019/4696843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Bachmann M, Lamprecht L, Gonther S, Pfeilschifter J, Mühl H. A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury. J Cell Mol Med 2020;24:10356-66. [PMID: 32697038 DOI: 10.1111/jcmm.15649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol Res. 2015;45:E1-E11. [PMID: 25472913 DOI: 10.1111/hepr.12459] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
35 Lim KP, Chun NA, Ismail SM, Abraham MT, Yusoff MN, Zain RB, Ngeow WC, Ponniah S, Cheong SC. CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One 2014;9:e103975. [PMID: 25153698 DOI: 10.1371/journal.pone.0103975] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
36 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:35-40. [PMID: 29594196 DOI: 10.5114/ceh.2018.73484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Afifi AM, El-Husseiny AM, Tabashy RH, Khalil MA, El-Houseini ME. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects. Asian Pac J Cancer Prev 2019;20:3007-13. [PMID: 31653148 DOI: 10.31557/APJCP.2019.20.10.3007] [Reference Citation Analysis]
38 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
39 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5. [PMID: 27239288 DOI: 10.12688/f1000research.6946.1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 11.7] [Reference Citation Analysis]
41 Chen WN, Liu LL, Jiao BY, Lin WS, Lin XJ, Lin X. Hepatitis B virus X protein increases the IL-1β-induced NF-κB activation via interaction with evolutionarily conserved signaling intermediate in Toll pathways (ECSIT). Virus Res. 2015;195:236-245. [PMID: 25449573 DOI: 10.1016/j.virusres.2014.10.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
42 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
43 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]